NEW YORK – New drugs are more likely to be approved if they target a gene linked to disease, according to a new analysis from AbbVie researchers that confirms earlier findings.
Only between 5 percent and 10 percent of new drug candidates that enter early-stage clinical trials are eventually approved. In 2015, researchers led by GlaxoSmithKline's Philippe Sanseau reported that drugs with supporting genetic evidence were twice as likely to be approved.